These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Polymorphism of dextromethorphan metabolism: relationships between phenotype, genotype and response to the administration of encainide in humans. Funck-Brentano C; Thomas G; Jacqz-Aigrain E; Poirier JM; Simon T; Béréziat G; Jaillon P J Pharmacol Exp Ther; 1992 Nov; 263(2):780-6. PubMed ID: 1432700 [TBL] [Abstract][Full Text] [Related]
10. CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication. Köhler D; Härtter S; Fuchs K; Sieghart W; Hiemke C Pharmacogenetics; 1997 Dec; 7(6):453-61. PubMed ID: 9429230 [TBL] [Abstract][Full Text] [Related]
11. CYP2D6 genotype and phenotype determination in a Mexican Mestizo population. López M; Guerrero J; Jung-Cook H; Alonso ME Eur J Clin Pharmacol; 2005 Nov; 61(10):749-54. PubMed ID: 16249913 [TBL] [Abstract][Full Text] [Related]
12. Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships. Chou WH; Yan FX; Robbins-Weilert DK; Ryder TB; Liu WW; Perbost C; Fairchild M; de Leon J; Koch WH; Wedlund PJ Clin Chem; 2003 Apr; 49(4):542-51. PubMed ID: 12651805 [TBL] [Abstract][Full Text] [Related]
13. Debrisoquin and S-mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian population. Marandi T; Dahl ML; Kiivet RA; Rägo L; Sjöqvist F Pharmacol Toxicol; 1996 May; 78(5):303-7. PubMed ID: 8737964 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325 [TBL] [Abstract][Full Text] [Related]
15. Cytochrome P450 2D6 and glutathione S-transferase genotype in sudden infant death syndrome. Chen CL; Liu Q; Evans WE; Sander CH; Relling MV J Paediatr Child Health; 1997 Feb; 33(1):31-7. PubMed ID: 9069041 [TBL] [Abstract][Full Text] [Related]
16. Genotype-sensitive reversible and time-dependent CYP2D6 inhibition in human liver microsomes. Storelli F; Desmeules J; Daali Y Basic Clin Pharmacol Toxicol; 2019 Feb; 124(2):170-180. PubMed ID: 30192434 [TBL] [Abstract][Full Text] [Related]
17. Serum dextromethorphan/dextrorphan metabolic ratio for CYP2D6 phenotyping in clinical practice. Jurica J; Bartecek R; Zourkova A; Pindurova E; Sulcova A; Kasparek T; Zendulka O J Clin Pharm Ther; 2012 Aug; 37(4):486-90. PubMed ID: 22548589 [TBL] [Abstract][Full Text] [Related]
18. No influence of CYP2D6*10 genotype and phenotype on the pharmacokinetics of nebivolol in healthy Chinese subjects. Luo X; Lei Y; He L; Liu W; Li M; Ran L; Yu M; Guo X; Yu P; Liu Z; Cheng Z J Clin Pharm Ther; 2015 Oct; 40(5):561-565. PubMed ID: 26214065 [TBL] [Abstract][Full Text] [Related]
19. Correlation of genotype, phenotype, and mRNA expression of CYP2D6 and CYP2C19 in peripheral blood leukocytes (PBLs). Kuhlmann JB; Wensing G; Kuhlmann J Int J Clin Pharmacol Ther; 2014 Feb; 52(2):143-50. PubMed ID: 24361088 [TBL] [Abstract][Full Text] [Related]
20. Genotype and phenotype of cytochrome P450 2D6 in human immunodeficiency virus-positive patients and patients with acquired immunodeficiency syndrome. O'Neil WM; Gilfix BM; Markoglou N; Di Girolamo A; Tsoukas CM; Wainer IW Eur J Clin Pharmacol; 2000 Jun; 56(3):231-40. PubMed ID: 10952478 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]